Group 1 - The company plans to issue convertible bonds with a total fundraising amount not exceeding RMB 700 million, with the specific amount to be determined by the board of directors [1] - The net proceeds from the fundraising will be allocated to three main projects: the construction of the Vietnam production base (Phase II), the industrialization of commercial and household energy storage systems, and the industrialization of smart grain storage robots [1][2] - The total investment for the Vietnam production base (Phase II) is RMB 345.96 million, with RMB 327.96 million expected to be funded from the bond issuance [2] Group 2 - The company has announced a plan to use up to RMB 1 billion of its own funds for cash management, which will be subject to approval at the upcoming shareholders' meeting [2] - The company aims to invest in financial products that are high in safety and liquidity, although there are potential risks associated with market fluctuations and financial institution failures [3] - The company has experienced a decline in net profit for two consecutive years and three quarters, with projected net profits of RMB 347 million, RMB 261 million, and RMB 181 million for the years 2022 to 2024, respectively [4][5]

Core Viewpoint - The Shanghai Stock Exchange's merger and acquisition review committee approved Nanjing Chemical Fiber Co., Ltd.'s asset purchase transaction, confirming it meets restructuring conditions and information disclosure requirements [1] Group 1: Transaction Structure - The transaction consists of a major asset swap, issuance of shares, and cash payment for asset purchases, all of which are interdependent and must be approved for the restructuring to be valid [2] - The company plans to swap all its assets and liabilities with an equivalent portion of the 52.98% stake in Nanjing Gongyi held by New Industrial Group [2] - The company intends to issue shares to New Industrial Group to purchase the remaining stake in Nanjing Gongyi, along with cash payments to 13 specific investors for their combined 47.02% stake [2] Group 2: Asset Valuation - The proposed valuation for the assets to be swapped is 72,927.12 million yuan, while the valuation for the assets to be acquired is 160,667.57 million yuan, based on assessments as of December 31, 2024 [3] - An extension assessment was conducted with results showing the swapped assets valued at 60,662.99 million yuan and the acquired assets at 163,969.96 million yuan, but these results will not affect the transaction pricing [4] Group 3: Share Issuance - The share issuance price for the asset purchase is set at 4.57 yuan per share, resulting in the issuance of 191,671,909 shares, which will represent 34.35% of the company's total shares post-transaction [4] Group 4: Related Party Transactions - The transaction is classified as a related party transaction, involving New Industrial Group and its affiliates, with related directors and shareholders abstaining from voting during board and shareholder meetings [5] - New Industrial Group is the controlling shareholder of Nanjing Gongyi, holding a total of 69.25% of its shares, with the actual controller being the Nanjing State-owned Assets Supervision and Administration Commission [5]

中国经济网北京1月8日讯 毛戈平（01318.HK）于1月6日晚间发布控股股东及董事减持股份计划。 毛戈平的独家保荐人、独家整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人为中国国 际金融香港证券有限公司；联席全球协调人、联席账簿管理人及联席牵头经办人为中国银河国际证券 （香港）有限公司、华泰金融控股（香港）有限公司、国泰君安证券（香港）有限公司、建银国际金融 有限公司；联席账簿管理人为农银国际融资有限公司、民银证券有限公司；联席牵头经办人为老虎证券 （香港）环球有限公司、富途证券国际（香港）有限公司、利弗莫尔证券有限公司。 毛戈平的最终发售价为29.80港元，所得款项总额为2,337.02百万港元，扣除按最终发售价计算之预计应 付上市开支149.76百万港元，所得款项净额为2,187.26百万港元。 招股书显示，毛戈平拟将全球发售所得款项按下述金额用于以下用途：所得款项净额约25.0%预期将用 于扩大公司的销售网络；所得款项净额约20.0%预期将用于品牌建设活动；所得款项净额约15.0%预期 将用于海外扩张及收购；所得款项净额约10.0%预期将用于加强公司的生产及供应链能力；所得款项净 额约9.0 ...

Core Viewpoint - Anpei Long (301413.SZ) has announced a plan to issue shares to specific investors, aiming to raise up to 544.4 million yuan for various sensor-related projects and working capital [1][2]. Group 1: Share Issuance Details - The share issuance will target no more than 35 specific investors, including qualified institutional investors and individuals, with all subscriptions made in cash at the same price [1]. - The pricing benchmark for the shares will be set at no less than 80% of the average trading price over the 20 trading days prior to the issuance date [1]. - The total number of shares to be issued will not exceed 15 million, representing 30% of the company's total shares before the issuance [1]. Group 2: Fund Utilization - The total amount to be raised is capped at 544.4 million yuan, which will be allocated to several projects, including: - Expansion of pressure sensor production (26.86 million yuan) - Upgrading of ceramic capacitive pressure sensor production lines (6.9 million yuan) - Construction of force sensor production lines (6.04 million yuan) - R&D and industrialization of MEMS sensor chips (5.64 million yuan) - Supplementing working capital (9 million yuan) [2][3]. Group 3: Ownership and Control - As of the announcement date, the actual controllers of the company are Wu Ruojun and Li Li, who collectively control 40.296% of the shares. The share issuance will not change the control of the company [4]. - The company went public on December 18, 2023, with an issuance of 18,923,500 shares at a price of 33.25 yuan per share, raising a total of 62.92 million yuan [4]. Group 4: Financial Performance - For the third quarter of 2025, the company reported a revenue of 308.23 million yuan, a year-on-year increase of 23.39%, and a net profit attributable to shareholders of 30.99 million yuan, up 14.09% [6][8]. - For the year-to-date period, the company achieved a revenue of 862.10 million yuan, reflecting a growth of 30.27%, with a net profit of 62.40 million yuan, an increase of 17.20% [7][8].

Core Viewpoint - Dongfang Tantalum Industry (000962.SZ) has received approval from the Shenzhen Stock Exchange for its issuance of securities to specific targets [1] Group 1: Issuance Details - The company disclosed its revised prospectus for the issuance of A-shares on January 7, 2025, targeting up to 35 specific investors, including China Nonferrous Metal Group and China Nonferrous Oriental Group [3] - The issuance constitutes a related party transaction, as both China Nonferrous Metal Group and China Nonferrous Oriental Group are affiliated with Dongfang Tantalum [3] - The total subscription amount from China Nonferrous Metal Group is RMB 105.27 million, while China Nonferrous Oriental Group will subscribe for RMB 480 million [3] Group 2: Financial Aspects - The issuance will adopt a pricing inquiry method, with the issue price set at no less than 80% of the average trading price over the 20 trading days prior to the pricing date [4] - The total amount raised from the issuance will not exceed RMB 1.1899 billion, with a net amount after deducting issuance costs to be invested in various projects, including the construction of a digital factory for tantalum and niobium [4] - The total investment for the projects is RMB 1.36348 billion, with the funds allocated as follows: RMB 566.50 million for the digital factory, RMB 253.20 million for the expansion of the smelting production line, RMB 254.61 million for the high-end product production line, and RMB 115.60 million for working capital [5]

Group 1 - The core point of the news is that ChaoXun Communication (603322.SH) announced the completion of a share reduction plan by its shareholder, Shanghai JiuYi Private Fund Management Co., Ltd., which reduced its holdings by 2,200,000 shares, accounting for 1.3961% of the total share capital [1][2] - The share reduction occurred between November 25, 2025, and January 7, 2026, with a total amount of 98,302,220 yuan, and the shares were sold at prices ranging from 34.89 yuan to 53.57 yuan per share [1] - Following the share reduction, Shanghai JiuYi's holdings decreased from 10,000,000 shares (6.35% of total shares) to 7,800,000 shares (4.9497% of total shares) [2] Group 2 - ChaoXun Communication received a warning from the Guangdong Securities Regulatory Bureau regarding issues in revenue recognition and internal controls, leading to inaccurate financial disclosures [3][4][5] - The company was found to have incorrectly recognized revenue for its customized computing server business and failed to report income accurately due to delays in data entry [4][5] - Internal control deficiencies were identified, including excessive credit limits for customers and inadequate management of accounts receivable, which resulted in legal actions against the company [6] Group 3 - In response to the warning, ChaoXun Communication's board and management have implemented corrective measures, including correcting financial statements and enhancing revenue recognition policies [7] - The company has committed to strengthening internal controls, improving the management of accounts receivable, and ensuring compliance with relevant regulations [7][8] - The board has also taken steps to hold responsible personnel accountable and improve their understanding of compliance requirements [8] Group 4 - On January 6, 2026, ChaoXun Communication announced that its controlling shareholder, Liang Jianhua, signed a share transfer agreement to sell 7,880,000 shares (5.00% of total shares) to Guangzhou Kangqi Asset Management Center at a price of 35.82 yuan per share, totaling 282,261,600 yuan [8][9] - After the transfer, Liang Jianhua's holdings will decrease from 32,285,000 shares (20.48%) to 24,405,000 shares (15.48%), while Guangzhou Kangqi will hold 7,880,000 shares [9] - This transfer will not change the controlling shareholder or actual controller of ChaoXun Communication [9]

2020年以后，羊婴幼儿奶粉发展进入瓶颈期，同期成人奶粉在疫情期间爆发式快速增长。疫情后的近两 年羊婴幼儿奶粉整体呈现下降趋势，表面看主要是小分子蛋白奶粉出现极大替代羊奶粉，小分子蛋白就 是为促进吸收率而添加部分水解蛋白的牛奶粉，其特点是价格相对便宜，且给渠道利润高。而羊奶粉从 2019年后开始打价格战，渠道利润严重下降，从而使得渠道放弃羊奶粉，改推小分子蛋白奶粉。我曾多 次说过，羊奶粉市场认知不足，至今依然是教育性产品。作为教育性产品，渠道需要足够的利润来维持 推广和教育活动，所以价盘稳定，利益分配清晰是核心。 成人奶粉在疫情期间快速发展，这与直播和私域兴起有关，同时线下密集精准的加大中老年教育。以往 老人自己购买奶粉占比不足十分之一，疫情后约40%老人形成自己稳定购买奶粉习惯，说明疫情后老人 主动开始喝奶粉。婴幼儿及中老年奶粉都属于专业性强的教育性产品，而会销是一种重要教育模式，但 是过去这些年不法分子用假冒伪劣产品通过会销欺骗和侵犯老人权益。所以，近两年羊成人奶粉也受到 极大影响，部分合法合规企业无辜中枪，在市场上形成劣币驱逐良币现象，引发各地区市场局严厉打 击。如果杜绝超额消费、夸张宣传，那么会销是一 ...

Group 1 - The central exchange rate of the Renminbi (RMB) against the US dollar is reported at 7.0197, which represents a depreciation of 10 basis points compared to the previous trading day [1] - The People's Bank of China has authorized the China Foreign Exchange Trade System to publish the exchange rates for various currencies against the RMB, including 1 Euro at 8.1769, 100 Japanese Yen at 4.4674, and 1 British Pound at 9.4207 [2] - The exchange rate for the RMB against other currencies includes 1 Australian Dollar at 4.7027, 1 New Zealand Dollar at 4.0371, and 1 Canadian Dollar at 5.0502, among others [2]

Group 1 - The National Medical Products Administration of China announced on January 6 that 28 batches of non-compliant drugs were identified, including sodium bicarbonate injection produced by China Resources Double Crane Pharmaceutical Co., Ltd. [1] - The specific non-compliance issue for the sodium bicarbonate injection (batch number: 24120602) was related to its pH value, which indicates the concentration of hydrogen ions and measures acidity or alkalinity [1]. - China Resources Double Crane Pharmaceutical Co., Ltd. was established in 2001 and is a member of China Resources Pharmaceutical Group, primarily engaged in the pharmaceutical manufacturing industry [2].

Group 1 - The National Medical Products Administration of China announced on January 6 that 28 batches of non-compliant drugs were identified, including sodium bicarbonate injection produced by Chenshin Pharmaceutical Co., Ltd., which failed due to visible foreign substances [1] - The visible foreign substances refer to insoluble materials that can be observed under specified visual conditions in injectable and ophthalmic solutions, typically with a particle size or length greater than 50 micrometers [2] Group 2 - Chenshin Pharmaceutical Co., Ltd. is a large comprehensive pharmaceutical enterprise engaged in research and development, production, and sales, listed on the Shanghai Stock Exchange main board in September 2017 [3] - The company is recognized as a national technology innovation demonstration enterprise and a national high-tech enterprise, and it serves as the vice president unit of the China Chemical Pharmaceutical Industry Association [3]